Cancer Res£ºË¥ÀÏϸ°ûÑÜÉúС°ûÍâÄÒÅݲ¢Òý·¢Î¢»·¾³Öа©Ï¸°û»ñµÃÐÔÄÍÒ©µÄ¹Ø¼ü»úÖÆ
¡¡5ÔÂ4ÈÕ£¬Öйú¿ÆÑ§ÔºÉϺ£ÓªÑøÓ뽡¿µÑо¿ËùËïÓî¿ÎÌâ×éÔÚÃÀ¹ú°©Ö¢Ñо¿Ð»á£¨AACR£©ºËÐÄÔÓÖ¾Cancer Research ÔÚÏß·¢±íÌâΪSenescent stromal cells promote cancer resistance through SIRT1 loss-potentiated overproduction of small extracellular vesicles µÄ³¤ÆªÂÛÎÄ¡£¸ÃÍŶӷ¢ÏÖÈËÔ´»ùÖÊϸ°ûÔÚ½øÈëË¥ÀÏ״̬֮ºó£¬»áÉú³É´óÁ¿µÄС°ûÍâÄÒÅÝ£¬ºóÕß³ÖÐø²»¶ÏµØ½øÈë΢»·¾³¿Õ¼ä¡£ÔÚ»¯ÁƱ³¾°Ïµİ©Ö¢»¼ÕßÌåÄÚ£¬Ë¥ÀÏϸ°ûÑÜÉúµÄС°ûÍâÄÒÅݼӾ粡ÔîÖвд氩ϸ°û¶ñÐÔ½øÕ¹²¢´ÙʹÆä»ñµÃÄÍÒ©ÐÔ£¬´Ó¶øÔì³ÉÁÙ´²»¼ÕßÏÔÖø½Ï²îµÄÔ¤ºó¡£´ËÍ⣬΢»·¾³ÖÐË¥ÀÏ»ùÖÊϸ°ûÊÍ·Å¡¢×îÖÕ½øÈëÍâÖÜѪѻ·µÄС°ûÍâÄÒÅÝʵ¼ÊÉÏÓм£¿ÉÑ£¬¼ìÑéÈËÔ±¿ÉÒÔͨ¹ý³£¹æÊֶμì²âÆäº¬Á¿µÄ¶¯Ì¬±ä»¯£¬´Ó¶ø¿É×÷Ϊ½«À´ÁÙ´²ÖÐÅжÏ×éÖ¯ËðÉ˺Ͳ¡ÈËÁƺóÉú´æµÄÒ»¸ö׼ȷָ±ê¡£
ÓÉϸ°ûÊͷŵ½°ûÍâ¿Õ¼äÖеÄĤÐÔÄÒÅÝ£¬Í³³ÆÎª°ûÍâÄÒÅÝ£¨extracellular vesicles, EVs£©£¬Ò»°ãÊÇÖ¬ÖÊË«·Ö×Ó²ã°üÈÆÐγɵİëÇò×´½á¹¹£¬¶øÆäÖÐÖ±¾¶ÔÚ30-150 nmÖ®¼äµÄÔòÊôÓÚС°ûÍâÄÒÅÝ¡£Ð¡°ûÍâÄÒÅÝ×÷Ϊϸ°û¼äתÔËÉúÎïĤ¡¢¿ÉÈÜ»ò½á¹¹ÐÔµ°°×¡¢¶àÖÖÖ¬ÖÊ¡¢ÒÅ´«ÎïÖʵÄÔØÌ壬´ú±í×ÅÒ»ÖÖÖØÒªµÄ°û¼äͨѶ·½Ê½¡£Ñо¿±íÃ÷£¬Ð¡°ûÍâÄÒÅݾßÓÐÖØÒªÉúÎ﹦ÄܺÍÌØ¶¨ÉúÀíÒâÒ壬¶øÆäÅŷŵÄÊýÁ¿¡¢ÖÖÀàÒÔ¼°ÄÚº¬ÔØÎïµÄ¹¹³É±ä»¯Óë¼²²¡ÃÜÇÐÏà¹Ø¡£¶ÔС°ûÍâÄÒÅݵÄÉîÈëÑо¿ÓÐÖúÓÚÀí½âÆäÉúÎ﹦ÄܺÍ×÷ÓûúÖÆ£¬Í¬Ê±Ò²ÓÐÖúÓÚ¼²²¡µÄÕï¶ÏºÍÖÎÁÆ£¬Òò¶øÓµÓо޴óµÄÁÙ´²Ó¦ÓÃǰ¾°¡£
Ë¥ÀÏϸ°ûÔÚÈËÌåË¥ÀϵĽø³ÌÖз¢»Ó׏ؼü×÷Ó㬽üÄêÀ´ÒѾ³ÉΪһ¸öÐÂÐ˺͸ßЧµÄ¿¹Ë¥Àϰе㡣˥ÀÏϸ°û¿ÉÒÔͨ¹ýSASp·ÖÃÚ¼¸Ê®ÉõÖÁÉϰÙÖÖ²»Í¬µÄµ°°×ÖÊ£¬ÆäÖв»ÉÙ×é·Öͬ˥Àϼ°Ë¥ÀÏÏà¹Ø¼²²¡ÓÐÖ±½ÓµÄÒò¹û¹ØÏµ£¬ÕâÒ²½âÊÍÁËΪºÎË¥ÀÏ»úÌå×ÜÊDZ»Ò»ÏµÁÐÑ×Ö¢Ïà¹ØÖ¢×´ËùÀ§ÈÅ¡£È»¶ø£¬ÈËÌåÄÚµÄË¥ÀÏϸ°ûÔÚ³öÏÖSASpµÄͬʱ£¬ÊÇ·ñÔÚС°ûÍâÄÒÅݵÄÉúÎïºÏ³ÉÓëÄÚº¹¹³ÉÉÏÒ²ÒѾ·¢ÉúÁËÉî¿Ì±ä»¯£¿Ò»µ©ÊÍ·Å£¬ÕâЩÄÒÅݶÔÓÚË¥ÀÏϸ°ûÖܱߵÄ΢»·¾³ÓкÎÓ°Ï죿ÊÇ·ñͬÈËÀàÖØ´ó¼²²¡Èç°©Ö¢µÄ½øÕ¹ÃÜÇÐÏà¹Ø£¿ÔÚÁÙ´²ÖÐÓ¦µ±ÈçºÎ׼ȷ¸ÉÔ¤£¿
Ñо¿ÈËÔ±·¢ÏÖ£¬Í¬»úÌåÕý³£Ï¸°ûÏà±È£¬Ë¥ÀÏ»ùÖÊϸ°ûÊͷŵÄС°ûÍâÄÒÅÝÊýÁ¿¡¢Á£¾¶ºÍ·Ö²¼·¶Î§¾ù·¢ÉúÉî¿Ì¸Ä±ä¡£Ë¥ÀÏϸ°ûÖб»¶¯¼¤»îµÄת¼»úÆ÷NF-¦ÊBÔÚÇý¶¯´óÁ¿SASpÒò×Ó²úÉúµÄͬʱ£¬Ò²Ïµ÷ÁËNAD+-ÒÀÀµÐÔÈ¥ÒÒõ£»¯Ã¸SIRT1ÕâÒ»¿¹Ë¥Àϵ°°×µÄ±í´ï¡£°éËæSIRT1½¥½øÐÔË¥Í˵ģ¬ÔòÊÇÈ«µ°°××é·ºËØ»¯Ë®Æ½µÄÃ÷ÏÔÉÏÉý¡£Óë´Ëͬʱ£¬¶àÑÇ»ùÒºÅÝH+-ATpase£¨V-ATpase£©µÄ´ß»¯ÑÇ»ùA£¨ATp6V1A£©±í´ï½µµÍ£¬Ôì³ÉË¥ÀÏϸ°ûÈÜøÌåËáÐÔ»¯£¨acidification£©¹¦ÄÜʧºâ£¬×îÖÕµ¼ÖÂС°ûÍâÄÒÅݵİûÄںϳÉÓë°ûÍâÊÍ·Å´ó·ùÔö¼Ó¡£ÔÚSIRT1¼¤»î¼ÁSRT2104£¨»òSRT1720£©µÄ×÷ÓÃÏ£¬Ë¥ÀÏ»ùÖÊϸ°ûºÏ³É°ûÍâÄÒÅݵÄÄÜÁ¦±»ÏÔÖø¿ØÖÆ¡£ÔÚÖ×Áö΢»·¾³ÖУ¬Ë¥ÀÏϸ°ûµÄ°ûÍâÄÒÅÝÄܹ»¸Ä±ä°©Ï¸°ûµÄ±í´ïÆ×£¬°üÀ¨ÒÔÁ×Ö¬õ£µ¨¼îΪµ×ÎïµÄp-Ìǵ°°×תÔ˼Ò×å³ÉÔ±ABCB4±í´ïÉϵ÷£¬¶øÆäËùÉæ¼°µÄÒ©ÎïÍâÅűûîÐÔËæÖ®ÉÏÉý¡£°©Ï¸°ûµÄÕâÒ»±ä»¯´Ù³ÉÁËÆä×ÔÉí¶Ô»¯ÁÆÒ©ÎïµÄÏÔÖøµÖ¿¹£¬¶øÇóýABCB4»òʹÓÃSRT2104ÔòÄÜÓÐЧ½µµÍË¥ÀÏ»ùÖÊϸ°ûС°ûÍâÄÒÅݸ³Óè΢»·¾³Öа©Ï¸°ûµÄÕâÖÖ»ñµÃÐÔÄÍÒ©µÄDZÁ¦¡£
×ÜÖ®£¬´ËÏîÑо¿½ÒʾÁËË¥ÀÏϸ°ûͨ¹ýSIRT1ϵ÷µ¼ÖÂС°ûÍâÄÒÅÝÉúÎïºÏ³ÉÓëÊÍ·Å»îÐÔµÄÔöÇ¿£¬Ôì³ÉÁÙ´²Ìõ¼þÏÂÖ×Áö΢»·¾³Öеݩϸ°û±íÏÖΪ»ñµÃÐÔÄÍÒ©¡¢¼Ó¿ì»¼ÕßÁƺó½×¶Î¼²²¡¸´·¢µÄÖØÒª»úÖÆ¡£ÖµµÃ×¢ÒâµÄÊÇ£¬¸Ã¹ý³ÌÖÐATp6V1AµÄ±í´ï½µµÍÔòʹµÃË¥ÀÏϸ°ûÈÜøÌåËáÐÔ»¯¹¦ÄÜÎÉÂÒ£¬¼ä½Ó½âÊÍÁËË¥ÀÏϸ°ûSA-¦Â-galȾɫÑôÐÔÂÊÉÏÉýÕâÒ»¾µäÏÖÏóµÄÔÒò£¬ºóÕß¶àÄêÀ´Ê¼ÖÕ×÷ΪÅжÏË¥Àϵıê×¼Ö®Ò»¶øÆäÉî²ã»úÖÆÏÊÓб¨µÀ¡£
ÓªÑøÓ뽡¿µËù²©Ê¿Éúº«ÁøºÍ¸´µ©´óѧÖÐɽҽԺÃÚÄòÍâ¿ÆÁúÆôÀ´Îª¸ÃÂÛÎĹ²Í¬µÚÒ»×÷Õߣ¬Ñо¿Ô±ËïÓîΪͨѶ×÷Õß¡£ÕâÏ×÷µÃµ½¸´µ©´óѧÖÐɽҽԺ½ÌÊÚ¹ù½£Ã÷¡¢ÖйúÒ½¿Æ´óѧ½ÌÊÚ²ÜÁ÷¡¢ËÕÖÝ´óѧ½ÌÊÚÇØéС¢Ó¢¹úÂ׶ص۹úÀí¹¤Ñ§Ôº½ÌÊÚEric LamºÍ±õÖÝҽѧԺ¸±½ÌÊÚ½ª¾²µÈµÄ´óÁ¦ÐÖú¡£¸ÃÑо¿»ñµÃ¹ú¼Ò¿Æ¼¼²¿¡¢×ÔÈ»¿ÆÑ§»ù½ðί¡¢ÖпÆÔºµÈ²¿Ãŵľ·Ñ×ÊÖú£¬Í¬Ê±Ò²µÃµ½ÓªÑøÓ뽡¿µËù¹«¹²¼¼Êõƽ̨ºÍ¶¯ÎïÆ½Ì¨µÄÖ§³Ö¡£
ÔÎıêÌ⣺
Senescent stromal cells promote cancer resistance through SIRT1 loss-potentiated overproduction of small extracellular vesicles